02nd week of 2015 patent applcation highlights part 43 |
Patent application number | Title | Published |
20150011576 | Inhibitors of Protein Kinases - The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases. | 2015-01-08 |
20150011577 | OXYMORPHONE CONTROLLED RELEASE FORMULATIONS - The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. | 2015-01-08 |
20150011578 | METHODS FOR IMPROVING MUSCLE STRENGTH - The present invention relates to methods for improving muscle strength and treating muscular dystrophy. | 2015-01-08 |
20150011579 | FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof - The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce fibroblast growth factor receptor (FGFR) dimerization, having the general formula: M | 2015-01-08 |
20150011580 | 1H-Pyrrolo [2, 3 -B] Pyridine Derivatives and Their Use as Radical Quenchers - The present disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased mitochondrial function resulting in diminished ATP production and/or oxidative stress and/or lipid peroxidation. | 2015-01-08 |
20150011581 | TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST - Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine). | 2015-01-08 |
20150011582 | Carboxamide Compounds and Methods for Using the Same - Disclosed are carboxamide compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 2015-01-08 |
20150011583 | OPTICALLY ACTIVE 2-HYDROXY TETRAHYDROTHIENOPYRIDINE DERIVATIVES, PREPARATION METHOD AND USE IN MANUFACTURE OF MEDICAMENT THEREOF - Optically active 2-hydroxytetrahydrothienopyridine derivatives represented by Formula I and pharmaceutically acceptable salts, preparation method and use in the manufacture of a medicament thereof are disclosed. The pharmacodynamic experiment results show that the present compounds of Formula I are useful for inhibiting platelet aggregation. The pharmacokinetic experiment results show that the present compound of Formula I can be converted in vivo into pharmacologically active metabolites and are therefore useful for inhibiting platelet aggregation. Therefore, the present compounds are useful for the manufacture of a medicament for preventing or treating thrombosis and embolism related diseases. | 2015-01-08 |
20150011584 | USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS - This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid. | 2015-01-08 |
20150011585 | ALPROSTADIL AND DYCLONINE FOR TREATMENT OF PREMATURE EJACULATION - Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C | 2015-01-08 |
20150011586 | Acyl Piperidine Inhibitors of Soluble Epoxide Hydrolase - Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. In some embodiments, the present invention provides a method for monitoring the activity of a soluble epoxide hydrolase, the method including contacting the soluble epoxide hydrolase with an amount of a compound of the present invention sufficient to produce a detectable change in the fluorescence of the soluble epoxide hydrolase by interacting with one or more tryptophan residues present in the catalytic site of said sEH. | 2015-01-08 |
20150011587 | ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION - Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C | 2015-01-08 |
20150011588 | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid - The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to a gastrointestinal disorder or disease in a subject in need thereof. In one aspect, the present invention provides a pharmaceutical composition comprising a proton pump inhibiting agent and a buffering agent for oral administration and ingestion by a subject. Upon administration, the composition contacts the gastric fluid of the stomach and increases the gastric fluid pH of the stomach to a pH that substantially prevents or inhibits acid degradation of the proton pump inhibiting agent in the gastric fluid and allows a measurable serum concentration of the proton pump inhibiting agent to be absorbed into the blood serum of the subject. | 2015-01-08 |
20150011589 | PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE MESYLATE AND POLYMORPHS OF INTERMEDIATES THEREOF - The present invention provides crystalline form of intermediates of Formula 2A, | 2015-01-08 |
20150011590 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2015-01-08 |
20150011591 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT - The present invention is directed to a compound of Formula I | 2015-01-08 |
20150011592 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions. | 2015-01-08 |
20150011593 | ARTIFICIAL SKIN - The present invention relates to a method for producing artificial skin, comprising: adding a matrix metalloproteinase inhibitor and a heparanase inhibitor to an artificial skin formation culture medium comprising human epidermal keratinocytes and human dermal fibroblasts, culturing the cells in the artificial skin formation culture medium, and forming artificial skin. | 2015-01-08 |
20150011594 | BIN1 EXPRESSION AS A MARKER OF CANCER - Provided are methods for screening a subject for cancer. The methods involve obtaining a blood sample from the subject and determining a level of Bridging Integrator 1 (BIND isoforms comprising exon 12a in the sample. Optionally, the method involves determining a level of 12a+/13− BIN isoform (comprising exon 12a but lacking exon 13) in the sample. An elevated level of 12a+ (e.g., 12a+/13−) BIN1 isoforms in the blood sample indicates the subject has cancer. Also provided are methods for determining efficacy of a cancer therapy in a subject and methods of treating cancer. Isolated antibodies that selectively bind human 12a+ BIN1 are also provided as well as kits for determining 12a+/13− BIN1 isoforms. | 2015-01-08 |
20150011595 | Inhibitors of Cholesterol Ester Transfer Protein - The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors. | 2015-01-08 |
20150011596 | TOPICAL LOCALIZED ISOXAZOLINE FORMULATION COMPRISING GLYCOFUROL - This invention provides topical localized formulations comprising an isoxazoline compound and a pharmaceutically or veterinary acceptable liquid carrier vehicle comprising glycofurol and an improved method for controlling, and preventing parasite infestation in animals. | 2015-01-08 |
20150011597 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention is directed to compounds of formula I: | 2015-01-08 |
20150011598 | PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN OR ESTER THEREOF AND CHLORTALIDONE, AND USE THEREOF - Provided is a pharmaceutical composition comprising candesartan or ester thereof and chlorthalidone, and use thereof, wherein the weight ratio of candesartan or ester thereof to chlorthalidone is 5.3:1 to 1:6.25. The pharmaceutical composition has a synergistic antihypertensive effect, and can enhance the antihypertensive effect and extend duration of antihypertension. | 2015-01-08 |
20150011599 | THICKENING COMPOSITION FOR USE IN AGROCHEMICAL FORMULATIONS, USE OF A THICKENING COMPOSITION AND AGROCHEMICAL FORMULATIONS CONTAINING A THICKENING COMPOSITION - The present invention describes a novel thickening composition that comprises a mixture of esters of an alkoxylated polyol and is used to enhance the viscosity of agrochemical formulations. The composition according to the present invention may present itself in solid for or in liquid form, in this latter case further comprising one or more surfactants, solvents, and optionally water. The thickening composition described in this invention is compatible with a large variety of pesticides and inert components used in agrochemical formulations, and it has evidence that it is capable of improving the stability and the effectiveness of the said formulations. | 2015-01-08 |
20150011600 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF - The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): | 2015-01-08 |
20150011601 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND A SUBSTITUTED IMIDAZOLE, METHODS AND USES THEREOF - This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to an animal in need thereof. | 2015-01-08 |
20150011602 | STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN - The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent; (b) methods of using such pharmaceutical dosage forms to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods. | 2015-01-08 |
20150011603 | ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS - The invention is directed to compounds according to formula (I): where R | 2015-01-08 |
20150011604 | Compounds for the treatment of neurodegenerative diseases - Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies. | 2015-01-08 |
20150011605 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression - Provided is a novel nucleic acid molecule that is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes, in sequence from the 5′ side to the 3′ side: a 5′ side region (Xc); an inner region (Z); and a 3′ side region (Yc). The inner region (Z) is composed of an inner 5′ side region (X) and an inner 3′ side region (Y) that are linked to each other. The 5′ side region (Xc) is complementary to the inner 5′ side region (X). The 3′ side region (Yc) is complementary to the inner 3′ side region (Y). At least one of the inner region (Z), the 5′ side region (Xc), and the 3′ side region (Yc) includes the expression inhibitory sequence. | 2015-01-08 |
20150011606 | COMPOSITIONS AND METHODS TO PROMOTE ERYTHROPOIESIS - Described herein are compositions and methods for enhancing erythropoiesis in an individual in need thereof. Specifically agents that decrease the expression of Exosc8, Exosc9, Dis3, Dis3L or Exosc10, such as inhibitory nucleic acid molecules, produce an increase in red blood cell production in the individual. | 2015-01-08 |
20150011607 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA - This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents. | 2015-01-08 |
20150011608 | iRNA Agents Targeting VEGF - The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified. | 2015-01-08 |
20150011609 | MICRORNAS FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION - The present invention discloses a set of human microRNAs, or a primary transcript for such microRNAs, or a precursor of such microRNAs, or a mimic of such microRNAs or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening microRNAs and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes. | 2015-01-08 |
20150011610 | METHOD FOR ENHANCING REMYELINATION USING GLI1 INHIBITORS - The invention provides a method of treatment of multiple sclerosis and other neurological disorders characterized by myelin loss or myelin deficiency by inhibiting Gli1 transcription factor. In a related aspect, the invention provides a method for enhancing neuroprotection of a central nervous system (CNS) or peripheral nervous system (PNS) neuron in a subject in need thereof comprising administering to said subject an effective amount of a Gli1 inhibitor. In one embodiment, the subject has a neurological disorder characterized by myelin loss or myelin deficiency. | 2015-01-08 |
20150011611 | INHIBITION OF THE GLYCINE CLEAVAGE SYSTEM FOR TREATMENT OF CANCER - In some aspects, methods of inhibiting survival or proliferation of a tumor cell are provided, the methods comprising inhibiting the glycine cleavage system (GCS) of the tumor cell. In some aspects, methods of treating a subject in need of treatment for a tumor, the method comprising inhibiting the GCS in the tumor. In some embodiments, the methods comprise contacting a tumor cell or tumor with a GCS inhibitor. In some embodiments, the tumor cell or tumor has elevated expression of serine hydroxymethyltransferase 2 (SH1VIT2). In some aspects, methods of identifying a tumor cell or tumor that is sensitive to inhibiting the GCS are provided, the methods comprising determining whether the tumor cell or tumor overexpresses SHMT2. In some aspects, methods of identifying a candidate anti-cancer agent are provided, the methods comprising identifying or modifying a GCS inhibitor. | 2015-01-08 |
20150011612 | RNAi MODULATION OF RSV AND THERAPEUTIC USES THEREOF - The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses. | 2015-01-08 |
20150011613 | METHODS AND COMPOSITIONS FOR PANIC DISORDERS - Methods and compositions that down regulate the activity of orexins to treat panic disorder and panic-like responses associated with hypercapnic conditions are disclosed. | 2015-01-08 |
20150011614 | METHODS AND COMPOSITIONS FOR TREATING INSECTS - Provided herein are methods and compositions for modulating gene expression in insects by administering a composition comprising an RNA effector molecule and a delivery agent. Methods are provided for controlling pest populations by inhibiting insect growth, development, survival, reproduction and/or viability. Also provided herein are methods for treating or preventing disease in an insect caused by a pathogen or by external factors (e.g., pollution, environment, stress, weather, etc.). | 2015-01-08 |
20150011615 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides - The present invention provides iRNA agents comprising at least one subunit of the formula (I): | 2015-01-08 |
20150011617 | COMBINED USE OF AMIDES OF MONO- AND DICARBOXYLIC ACIDS AND SILYMARIN IN THE TREATMENT OF RENAL DISEASES - A therapy for renal diseases characterized by alterations of the kidney function, such as Chronic Kidney Disease (CKD), acute and chronic renal impairment, and renal diseases that develop in diabetic patients or in patients who underwent an anticancer chemotherapic treatment with a platinum derivative. The invention is a combination of compounds selected from mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol, and compounds selected from Silymarin, derivatives thereof or conjugates or complexes thereof, for use in the treatment of renal diseases. The mono- or diamide of a C12-C20 monocarboxylic acid, saturated or monounsaturated, or of a C4-C14 dicarboxylic acid, saturated or monounsaturated, with an aminoalkanol and said Silymarin, derivatives thereof or conjugates or complexes thereof are formulated for a separate, sequential, concomitant administration or in admixture, also in a co-micronized or co-ultra-micronized form. | 2015-01-08 |
20150011618 | SYNTHESIS OF POLYHYDROXY CHROMENONE COMPOUNDS AND THEIR ANTI-TUMOR EFFECTS - The present invention is directed to chromenone compounds of formula (I), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor ER-α36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc. | 2015-01-08 |
20150011619 | METHOD OF TREATMENT FOR ACNE AND AN ANTI-ACNE FORMULATION - The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; | 2015-01-08 |
20150011620 | ANTI-INVASIVE COMPOUNDS - The present invention relates to the field of anti-invasive compounds and methods for predicting the anti-invasive activity of said compounds, as well as their use in the prevention and/or treatment of diseases associated with undesired cell invasion; in particular, this invention relates to the field of anti-invasive chalcone-like compounds. | 2015-01-08 |
20150011621 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS - Formylated xanthocillin analogs can be used in the treatment of neurodegenerative diseases. The analogs can be prepared synthetically, and at least some of the analogs can be obtained from a microorganism strain of the | 2015-01-08 |
20150011622 | Dosage Form Containing Extract From Bark of Liriodendron Tulipifera as Active Ingredient - The present invention relates to an improved dosage form containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of | 2015-01-08 |
20150011623 | Pharmaceutical Composition Containing as Active Ingredient Extract From Bark of Liriodendron Tulipifera - The present invention relates to a pharmaceutical composition containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of | 2015-01-08 |
20150011624 | Method for extracting treatment ingredients for gastrointestinal diseases from bark of liriodendron tulipifera - The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of | 2015-01-08 |
20150011625 | METHODS FOR TREATING FIBROMYALGIA SYNDROME - The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof. | 2015-01-08 |
20150011626 | METHODS OF TREATING AND PREVENTING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM - Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammatory agent to the patient. Examples of the anti-inflammatory agent include glutathione and inhibitors of purinergic receptors such as P2X | 2015-01-08 |
20150011627 | TRITERPENOIDS AND COMPOSITIONS CONTAINING THE SAME - The present invention provides triterpenoids produced from natural compounds such as oleanolic acid, ursolic acid, betulinic acid, and hederagenin. | 2015-01-08 |
20150011628 | SUBSTITUTE DIPHENYLAMINE COMPOUNDS USE THEREOF AS ANTITUMOR AGENTS - The invention relates to substituted diphenylamine compounds using as antitumor agents. The structure of the compounds is represented as the general formula (I): | 2015-01-08 |
20150011629 | BIOACTIVE DEPSIDE AND ANTHOCYANIN COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (IV): Formula (IV) wherein R is selected from H or CH | 2015-01-08 |
20150011630 | DIHYDROXYPHENYL NEUROTRANSMITTER COMPOUNDS, COMPOSITIONS AND METHODS - The present invention relates to new dihydroxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof. | 2015-01-08 |
20150011631 | Cetylated fatty acid and alkali buffered creative anti-inflammatory composition - An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment. | 2015-01-08 |
20150011632 | IN SITU GENERATION OF PEROXYCARBOXYLIC ACIDS AT ALKALINE pH, AND METHODS OF USE THEREOF - The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed. | 2015-01-08 |
20150011633 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES - Pharmaceutical formulations containing lipoic acid derivatives are made. | 2015-01-08 |
20150011634 | AQUEOUS LIQUID PREPARATION CONTAINING 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID - An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.). | 2015-01-08 |
20150011635 | DICLOFENAC TOPICAL FORMULATION - The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. | 2015-01-08 |
20150011636 | METHOD FOR TREATMENT OF DISEASES WITH DIOXOANTHRACENE SULPHONATE DERIVATIVES - Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R | 2015-01-08 |
20150011637 | CRYSTAL FORM OF PROSTAGLANDIN ANALOGUE, AND PREPARATION METHOD AND USE THEREOF - Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9±0.2°, 6.5±0.2°, 12.6±0.2°, 13.1±0.2° and 20.6±0.2°. | 2015-01-08 |
20150011638 | ALPROSTADIL AND LIDOCAINE TREATMENT OF PREMATURE EJACULATION - Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C | 2015-01-08 |
20150011639 | SULFONAMIDES FOR THE PREVENTION OF DIABETES - The use of sulfonamides of formula (I) | 2015-01-08 |
20150011640 | GYNECOLOGIC COMPOSITION TO TREAT VULVAR VESTIBULITIS - A gynecologic composition contains spermidine to treat vulvar vestibulitis syndrome (VVS). In this therapeutic context, spermidine is effective at around one micromole per applied dose in the form of a simple salt or complex, alone or in combination or in conjunction with auxiliary actives such as anaesthetics and estrogens. | 2015-01-08 |
20150011641 | HIGH LOAD DISPERSIONS - The present invention relates to the field of carrier and delivery systems for active molecular compounds. In particular, the present invention provides aqueous dispersions for delivery of active molecular compounds. | 2015-01-08 |
20150011642 | GREASE-LIKE GEL FOR REPELLING INSECTS AND PREVENTING UNDESIRABLE BEHAVIOR IN HOOFED ANIMALS - Grease-like compositions are provided for repelling insects and preventing undesirable behavior in hoofed animals. The compositions utilize nontoxic mineral, synthetic, or vegetable oil based gels containing silica, clay, urea, polytetrafluoroethylene, or metallic soap thickeners and capsaicin. | 2015-01-08 |
20150011643 | TREATMENT OF HEART FAILURE AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS - Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure. | 2015-01-08 |
20150011644 | Methods and Compositions for Deterring Abuse - A therapeutic composition comprising: a methamphetamine precursor; a gel-forming polymer; an emulsifier with a lipid backbone; a disintegrant; and a surfactant; wherein the ratio of emulsifier to gel-forming polymer on a weight basis is between about 10:1 and 1:10. | 2015-01-08 |
20150011645 | AMINE DENDRIMERS - Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia. | 2015-01-08 |
20150011646 | USAGE OF GUTTIFERONE K, A NATURAL COMPOUND FROM GARCINIA YUNNANENSIS HU ON TREATING HIGH METASTATIC ESOPHAGEAL CANCER - This invention is related to compounds isolated from various | 2015-01-08 |
20150011647 | ANTIBACTERIAL AGENTS: PHLOROGLUCINOL DERIVATIVES - The invention provides a compound of formula I: | 2015-01-08 |
20150011648 | PROCESS FOR THE MAINTAINING OF A RATIO OF ISOMERS OF CAROTENOID COMPOUNDS - The present invention relates to process for the maintaining of a ratio stereoisomers of carotenoid compounds, to specific formulations and to the use of such specific formulations. | 2015-01-08 |
20150011649 | METHODS OF TREATING INFECTIOUS DISEASES - The present invention provides methods of treating a human or other mammal infected with a parasitic microorganism by administering an effective amount in unit dosage form of a C | 2015-01-08 |
20150011650 | METHOD FOR TREATING NON-MELANOMA SKIN CANCER BY INDUCING UDP-GLUCURONOSYLTRANSFERASE ACTIVITY USING PTEROSTILBENE - A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene. | 2015-01-08 |
20150011651 | ALCOHOLIC COMPOSITIONS HAVING A LOWERED RISK OF ACETALDEHYDEMIA - The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. | 2015-01-08 |
20150011652 | FOAMING ALCOHOL COMPOSITIONS WITH SELECTED DIMETHICONE SURFACTANTS - Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products. | 2015-01-08 |
20150011653 | Novel Microbial Pathogen inhibitor - A formulation containing xylitol is used in a variety of ways to inhibit the ability of microorganisms to adhere to mucus membranes in the lungs throat, bladder, colon, ears, skin and rectum, and subsequently infect the host. | 2015-01-08 |
20150011654 | STABLE WATER-IN-OIL EMULSIONS WITH HLB-TYPE EMULSIFIERS - Cosmetic and/or dermatological preparations based on a water-in-oil emulsion comprising at least two W/O emulsifiers which differ in their HLB value up to a maximum of 1 lead to sensorily acceptable preparations and at the same stable W/O emulsions. | 2015-01-08 |
20150011655 | FLOW SYSTEM METHOD FOR PREPARING SUBSTANTIALLY PURE NANOPARTICLES, NANOPARTICLES OBTAINED BY THIS METHOD AND USE THEREOF - The invention relates to a method of synthesis of substantially pure nanoparticles in a continuous-flow system, in which a precursor substance solution undergoes reduction reaction using a reducing agent solution and nanoparticles are produced, wherein the reduction reaction is terminated by adding an agent neutralizing the reducing agent and a stable nanoparticle colloid is produced. In the method of the invention a need for using surfactants or other organic molecules for nanoparticle stabilization has been eliminated. | 2015-01-08 |
20150011656 | Co-Modified Organopolysiloxane, Emulsifier For Water-In-Oil Emulsion, External Use Preparation, And Cosmetic Composition Using The Same - A co-modified organopolysiloxane represented by General Formula (1): R | 2015-01-08 |
20150011657 | Live poly(n-vinyl lactam) reactive stabilizers for dispersed phase polymerization - The present invention concerns a method for preparing a polymer comprising a step (EI) for dispersed phase polymerization in the presence of a reactive stabiliser, wherein the following are brought into contact in an aqueous phase:—at least one ethylenically unsaturated monomer;—at least one source of free radicals; and—a reactive stabiliser comprising a polymer chain including monomer units (N-vinyl lactam) and a thiocarbonylthio-S group (C═S)—. | 2015-01-08 |
20150011658 | NOVEL SILICONE ACRYLATE AND ACRYLIC ACID THICKENING POLYMER REDUCING THE STICKINESS OF GLYCERINE-BASED COSMETIC FORMULAS - An anionic polyelectrolyte resulting from the polymerisation: a) of a mass ratio greater than or equal to 80% and less than or equal to 99.5% of monomeric units from a monomer with a weak acid function; b) of a mass ratio greater than or equal to 0.5% and less than or equal to 20%, —Either of a monomer of formula (la): R—(CH | 2015-01-08 |
20150011659 | LOW PROTEIN PERCENTAGE GELLING COMPOSITIONS - Described herein are low protein concentration gelling compositions comprising keratin proteins. | 2015-01-08 |
20150011660 | High-Purity Rubusoside And Process For Producing Of The Same - The invention provides a process of producing Rubusoside from steviol glycosides of Stevia rebaudiana plant. The process is useful for producing high purity Rubusoside with purity greater than 95% (dry basis). High purity rubusoside is useful as in combination with other caloric and non-caloric sweeteners as well as non-caloric sweetener in various food and beverage compositions. The high purity rubusoside is useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectionaries, bakeries, cookies, chewing gums, and alike. | 2015-01-08 |
20150011661 | HYDROPHILIC SILICONE MONOMERS, PROCESS FOR PREPARATION THEREOF AND THIN FILMS CONTAINING THE SAME - The present invention relates to a fast curing compositions comprising a (meth)acrylamide functionalized hydrophilic silicone monomers having a polyether moiety containing a branched linking group. In one embodiment, such compositions are useful for preparing water-absorbing silicone-hydrogel films for contact lens applications. In one embodiment, the (meth)acrylamide monomers disclosed here have a branched linking group on the polyether moiety which makes it possible to produce hydrophilic polyether modified silicone copolymers without the need to separate various by-products including, but not limited to, unreacted, isomerized polyether and associated high molecular weight by-products. | 2015-01-08 |
20150011662 | HYDROCARBON PRODUCTION APPARATUS AND HYDROCARBON PRODUCTION PROCESS - The hydrocarbon production apparatus is provided with a gas-liquid separator for cooling gaseous state hydrocarbons drawn out from a gas phase portion of a reactor for the Fischer-Tropsch synthesis reaction and liquefying a portion of the hydrocarbons. A light liquid hydrocarbon supply line for supplying light hydrocarbons is disposed between a downstream side line which is downstream from the last stage of a gas-liquid separating unit of the gas-liquid separator, and an upstream side line which is upstream from the last stage of the gas-liquid separating unit of the gas-liquid separator, wherein the downstream side line is a liquid hydrocarbon line on the downstream side through which the light hydrocarbons having cloud points lower than the temperature at an outlet of a cooler in the last stage of the gas-liquid separating unit are flowed. | 2015-01-08 |
20150011663 | PROCESS FOR PREPARING A PARAFFIN PRODUCT - The invention relates to a process for preparing a paraffin product from a carbonaceous feedstock comprising (a) partial oxidation of the carbonaceous feedstock to obtain a mixture comprising hydrogen and carbon monoxide, (b) performing a Fischer-Tropsch reaction using the mixture as obtained in step (a) and recovering an off-gas from the Fischer-Tropsch reaction and a paraffin product, (c) hydrogenating at least a part of the off-gas from the Fischer-Tropsch reaction using a steam/off-gas mol ratio in the range of between 0.5 and 1.5 and a catalyst comprising copper and zinc, followed by a conversion step (d) using a nickel based catalyst, and (e) preparing a hydrogen comprising gas from at least a part of the off-gas from the Fischer-Tropsch reaction. | 2015-01-08 |
20150011664 | PELLET BASED TOOLING AND PROCESS FOR BIODEGRADABLE COMPONENT - An example starch-based material for forming a biodegradable component includes a mixture of a starch and an expansion additive. The starch has an amylose content of less than about 70% by weight. The expansion additive enhances the expansion and physical properties of the starch. A method of preparing a starch-based material is also disclosed and an alternate starch-based material for forming a biodegradable component is also disclosed. | 2015-01-08 |
20150011665 | Foamed Articles Exhibiting Improved Thermal Properties - Cellular and multi-cellular polystyrene and polystyrenic foams and methods of forming such foams are disclosed. The foams include an expanded polystyrene formed from expansion of an expandable polystyrene including an adsorbent comprising alumina, wherein the multi-cellular polystyrene exhibits a multi-cellular size distribution. The process for forming a foamed article includes providing a formed styrenic polymer and contacting the formed styrenic polymer with a first blowing agent and an adsorbent comprising alumina to form extrusion polystyrene. The process further includes forming the extrusion styrenic polymer into an expanded styrenic polymer and forming the expanded styrenic polymer into a foamed article. | 2015-01-08 |
20150011666 | SYSTEMS AND METHODS FOR MANUFACTURING FOAM PARTS - This disclosure relates generally to molded cellular foam parts and, more specifically, to methods of manufacturing cellular polyurethane foam parts. In an embodiment, a polymer production system includes an energy source configured to provide activation energy to a foam formulation to produce a foam part. The system further includes a polymeric mold configured to contain the foam formulation within a mold cavity during the manufacture of the foam part. Furthermore, the mold is configured to not substantially interact with the activation energy that traverses the mold during the manufacture of the foam part. The system also includes a semi-permanent surface coating disposed on a surface of the mold cavity that is configured to facilitate release of the foam part from the mold cavity. | 2015-01-08 |
20150011667 | HYDROPHILIC MACROMERS AND HYDROGELS COMPRISING THE SAME - A composition, suitable for use in producing hydrogel polymer films from which biomedical devices such as contact lenses can be made, comprising at least one hydrophilic silicone macromer. In one aspect, a hydrophilic silicone macromer is of the Formula 1: | 2015-01-08 |
20150011668 | NANOSTRUCTURED MATERIALS AND METHODS OF MAKING THE SAME - Material comprising submicrometer particles dispersed in a polymeric matrix. The materials are useful in article, for example, for numerous applications including display applications (e.g., liquid crystal displays (LCD), light emitting diode (LED) displays, or plasma displays); light extraction; electromagnetic interference (EMI) shielding, ophthalmic lenses; face shielding lenses or films; window films; antireflection for construction applications; and construction applications or traffic signs. | 2015-01-08 |
20150011669 | HYDROPHILIC MACROMERS AND HYDROGELS COMPRISING THE SAME - A hydrophilic silicone macromer composition suitable for use in producing hydrogel polymer films from which biomedical devices such as contact lenses can be made. The hydrophilic silicone macromer comprises a polyether backbone comprising a silicone-containing pendant group. In one aspect, a hydrophilic silicone macromer is of the Formula 1: | 2015-01-08 |
20150011670 | POLYMERIZABLE AMIDO-CONTAINING ORGANOSILICON COMPOUNDS, SILICON-CONTAINING POLYMERS AND BIOMEDICAL DEVICES THEREFROM - There is provided a fast curing composition comprising an alpha, beta-unsaturated amido-containing organosilicon compound, useful in making water absorbing silicone-hydrogel films for biomedical devices, such as contact lens, and a process for producing these monomers. This invention also provides for hydrogels made from the alpha, beta-unsaturated amido-containing organosilicon compound described herein. | 2015-01-08 |
20150011671 | ORGANO-MODIFIED SILICONE POLYMERS AND HYDROGELS COMPRISING THE SAME - A hydrophilic silicone polymer composition suitable for use in producing hydrogel polymer films disclosed. In one aspect, a hydrophilic silicone monomer is of the Formula 1: | 2015-01-08 |
20150011672 | SILICONE HYDROGELS HAVING A STRUCTURE FORMED VIA CONTROLLED REACTION KINETICS - The present invention relates to a process comprising the steps of reacting a reactive mixture comprising at least one silicone-containing component, at least one hydrophilic component, and at least one diluent to form an ophthalmic device having an advancing contact angle of less than about 80°; and contacting the ophthalmic device with an aqueous extraction solution at an elevated extraction temperature, wherein said at least one diluent has a boiling point at least about 10° higher than said extraction temperature. | 2015-01-08 |
20150011673 | ORGANIC/INORGANIC COMPOSITE, MANUFACTURING METHOD THEREFOR, DENTAL MATERIAL, AND BONE SUBSTITUTE MATERIAL - Provided are: an organic/inorganic composite, and a manufacturing method therefor; and a dental material and bone substitute material manufactured using the organic/inorganic composite. The organic/inorganic composite includes: (A) 100 parts by mass of a thermoplastic resin containing as a main component at least one kind selected from a polyarylketone resin and a polysulfone resin; and (B) 60 to 300 parts by mass of an inorganic particle mixture dispersed in the thermoplastic resin, in which the inorganic particle mixture contains inorganic particles each having a particle diameter of from 200 to 700 nm at a content of 25 vol % or more, and inorganic particles each having a particle diameter of from 40 to 100 nm at a content of 10 vol % or more. | 2015-01-08 |
20150011674 | MICROCAPSULES - A composition is provided, comprising microcapsules,
| 2015-01-08 |
20150011675 | COATING COMPOSITION AND COATING FILM OBTAINED FROM COATING COMPOSITION - The present invention aims to develop an aqueous heat-shielding coating material to which low staining properties are imparted to suppress a reduction in heat-shielding properties due to the reduction in solar reflectance caused by adhesion of contaminants in the air during outdoor exposure, thereby maintaining the heat-shielding properties for a long period of time. The above problem is solved by providing a resin composition for an aqueous coating material including: (A1) a water-soluble and/or water-dispersible resin; (A2) a heat-shielding pigment; (B1) an organosilicate and/or a modified product of the organosilicate; and (B2) a curing catalyst that promotes a hydrolysis/condensation reaction of an alkoxysilyl group. | 2015-01-08 |
20150011676 | RUBBER COMPOSITION FOR TIRE AND PNEUMATIC TIRE - A rubber composition for a tire includes a rubber component, aluminum hydroxide particles having an average particle diameter in a range of 1.5 μm or smaller and a nitrogen adsorption specific surface area of 3˜60 m | 2015-01-08 |